ImmunityBio, Inc. (IBRX)
NASDAQ: IBRX · Real-Time Price · USD
2.690
+0.200 (8.03%)
May 15, 2025, 1:42 PM - Market open
ImmunityBio Revenue
ImmunityBio had revenue of $16.52M in the quarter ending March 31, 2025, with 41,192.50% growth. This brings the company's revenue in the last twelve months to $31.22M, up 10,238.41% year-over-year. In the year 2024, ImmunityBio had annual revenue of $14.75M with 2,270.58% growth.
Revenue (ttm)
$31.22M
Revenue Growth
+10,238.41%
P/S Ratio
59.21
Revenue / Employee
$45,915
Employees
680
Market Cap
2.37B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
IBRX News
- 3 days ago - ImmunityBio Reports Doubled Net Revenue and 150% Unit Growth in Q1 2025, With Continued Strong Sales Momentum in First Quarter since J-code - Business Wire
- 9 days ago - ImmunityBio: Getting Whiplash After FDA's Refusal To File For Anktiva's sBLA - Seeking Alpha
- 10 days ago - ImmunityBio Slapped With FDA Refusal To File Letter For Expanded Use Of Its Bladder Cancer Drug - Benzinga
- 10 days ago - ImmunityBio Requests an Urgent Meeting With FDA to Address the Change in the Agency's Unambiguous Guidance on Jan 2025 to Submit a sBLA for NMIBC BCG Unresponsive Papillary Disease, Following an Inconsistent Refusal to File Letter on May 2, 2025 - Business Wire
- 16 days ago - ImmunityBio Q1 Earnings Preview: I Fear A Selloff, But Am Long-Term Bullish - Seeking Alpha
- 17 days ago - Unmatched Long-Term Bladder Preservation for 36 Months in over 80 percent of Responders with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC CIS and Papillary Disease Alone – Best in Disease and Best in Class with 5 Year Follow-Up - Business Wire
- 23 days ago - ImmunityBio to Showcase Advances for Bladder and Prostate Cancer at American Urological Association (AUA) Annual Meeting - Business Wire
- 4 weeks ago - ImmunityBio Announces FDA Submissions of Supplemental BLA for NMIBC Papillary Disease and for Expanded Access of ANKTIVA® to Treat Lymphopenia - Business Wire